2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123485
    PPI-1019 290828-45-4 98%
    PPI-1019 is an amyloid beta (Aβ) inhibitor. PPI-1019 can be used in the research of neurological diseases and Alzheimer's disease.
    PPI-1019
  • HY-123492
    Kentsin 56767-30-7 98%
    Kentsin (Thr-Pro-Arg-Lys), a contraceptive tetrapeptide, is originally extracted from hamster embryos. Kentsin prevents the maturation of Graafian follicles and consequently inhibits ovulation, without binding to opioid receptors. Kentsin has opiate properties on gastrointestinal motility.
    Kentsin
  • HY-123501
    MitoE10 1810703-64-0 98%
    MitoE10 is potent antioxidant agent. MitoE10 prevents lipid peroxidation, mitochondrial oxidative damage and damage to mitochondrial DNA.
    MitoE10
  • HY-123525
    COR628 550310-04-8 98%
    COR628 is a positive allosteric modulator of GABA(B) receptors with the activity of enhancing GABA-induced GTPγS stimulation. COR628 showed significant activity in in vitro studies but did not exhibit endogenous agonist activity. COR628 has shown efficacy in experiments in mice by enhancing the sedation/hypnosis induced by baclofen, shortening the onset time and extending the duration of loss of righting reflex when combined with non-sedating doses of baclofen . The cytotoxic effect of COR628 is comparable to or higher than that of GS39783 or BHF177 in concentration.
    COR628
  • HY-12355S
    Siponimod-d11 2104759-32-0 98%
    Siponimod-d11 (BAF-312-d11) is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research.
    Siponimod-d11
  • HY-123567
    LY86057 148966-66-9 98%
    LY86057 is an ergoline derivative without N1 substituents. It has higher affinity for porcine, squirrel monkey and human 5-HT2 receptors than rats and is an antagonist of 5-HT2 receptors. When studying the differences in recognition of a series of ergolines between species, LY86057 was found to be more selective for 5-HT2 receptors. Compared with LY53857, LY108742 resulted in a higher affinity for rat 5-HT2 receptors even when the N1 substituent was only methyl.
    LY86057
  • HY-123594
    R-2 Methanandamide 157182-47-3 98%
    R-2 Methanandamide (Compound 2) is a cannabinoid Anandamide (HY-10863) analog with a Ki of 119 nM for the cannabinoid receptor (Ki is determined using rat brain membranes with PMSF).
    R-2 Methanandamide
  • HY-123654
    L-796449 194608-80-5 98%
    L-796449 is a potent PPARγ agonist. L-796449 shows neuroprotective. L-796449 has the potential for the research of stroke.
    L-796449
  • HY-123655
    Fenazinel dihydrochloride 685138-02-7 98%
    Fenazinel dihydrochloride, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows promise as a potential treatment for ischemic stroke.
    Fenazinel dihydrochloride
  • HY-123661
    MIPS1455 1627580-82-8 98%
    MIPS1455 is a light-activated M1 muscarinic acetylcholine receptor ligand with irreversible binding activity to the allosteric site of the receptor. MIPS1455 is a drug target under investigation for the suppression of cognitive deficits and may become a valuable molecular tool for further investigation of allosteric interactions of the receptor.
    MIPS1455
  • HY-123677
    E2508 685886-34-4 98%
    E2508 is an orally active corticotropin-releasing factor 1 (CRF1) receptor antagonist with a Ki value of 11 nM for hCRF1.
    E2508
  • HY-123704
    CGS-12066 maleate 1350965-83-1 98%
    CGS-12066 (maleate) is a 5-HT receptor agonist. CGS-12066 has agonist effect for 5-HT1A , 5-HT1B ,5-HT1C and 5-HT1D with pEC50 values of 6.41, 7.56, 4.05 and 7.11, respectively. CGS-12066 can be used for the research of neurological disease.
    CGS-12066 maleate
  • HY-123743
    JNJ-42314415 1334165-90-0 98%
    JNJ-42314415 is a centrally active phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 35 nM and 64 nM for human recombinant PDE10A and rPDE10A, respectively.
    JNJ-42314415
  • HY-123807
    JNJ-5234801 426227-09-0 98%
    JNJ-5234801 is an orally active anxiolytic that targets the 5-HT2 receptor. In rats, JNJ-5234801 increases water intake and reduces alcohol preference. JNJ-5234801 could be used in studies on anxiety and alcoholism.
    JNJ-5234801
  • HY-123836
    MK-7288 936626-07-2 98%
    MK-7288 is a histamine H3 receptor inverse agonist. MK-7288 can prolong sleep latency in the Maintain Wake Test (MWT). MK-7288 can be used in research on obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS).
    MK-7288
  • HY-12383S
    Pelubiprofen-13C,d3 98%
    Pelubiprofen-13C,d3 is the 13C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects.
    Pelubiprofen-13C,d3
  • HY-123858
    VU6001221 2002495-17-0 98%
    VU6001221 is a blood-brain barrier permeable CHT inhibitor (IC50 = 270 nM). VU6001221 increases the likelihood of extracellular choline elevation activating synaptic α7 nicotine ACh receptors. VU6001221 attenuates potassium-induced ACh levels in the prefrontal cortex.
    VU6001221
  • HY-123874
    BMS-952048 1375751-32-8 98%
    BMS-952048 is a positive allosteric modulator of mGluR5 with an EC50 of 10 nM.
    BMS-952048
  • HY-12390A
    Lofepramine hydrochloride 26786-32-3 98%
    Lofepramine (Lopramine) is a modified tricyclic and orally active antidepressant. Lofepramine inhibits the uptake of Noradrenaline (NA) (HY-13715) and 5-hydroxytryptamine (5-HT) with IC50s of 2.7 μM and 11 μM, respectively. Lofepramine exerts its antidepressant activity by promoting noradrenergic neurotransmission. Lofepramine also enhances serotonergic neurotransmission by inhibiting neuronal uptake of 5-HT and tryptophan pyrrolase. Lofepramine exhibits significant anxiolytic properties. .
    Lofepramine hydrochloride
  • HY-123970
    ISO-92 899433-49-9 98%
    ISO-92 in an inhibitor of MIF. ISO-92 selectively inhibits MIF inflammatory activity with an IC50 of 550 nM. ISO-92 inhibits hypoxia-induced proliferation of CCL-210 cell line dose-dependently. ISO-92 significantly reduces the thickness of pulmonary vascular wall in mouse hypoxia models. ISO-92 can be studied in inflammatory and neurological research.
    ISO-92
Cat. No. Product Name / Synonyms Application Reactivity